Skip to main content

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe

Clinical Trial Grant
Duke Scholars

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 7, 2025
 

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 7, 2025